N-phenylacetoaminomethylene-DL-p-nitrophenylalanine clinical trials
How each study uses N-phenylacetoaminomethylene-DL-p-nitrophenylalanine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2017 (4)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 0
Studies
Open first, then newest update. How each study uses N-phenylacetoaminomethylene-DL-p-nitrophenylalanine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- Study of A-101 for the Treatment of Seborrheic KeratosisCompletedPhase 2Aclaris Therapeutics, Inc.NCT02260180Written as A-101How we know
- Safety Study of A-101 Topical Solution for the Treatment of Common WartsCompletedPhase 3Aclaris Therapeutics, Inc.NCT03812510Written as A-101How we know
- Study of A-101 Topical Solution for the Treatment of Common WartsCompletedPhase 3Aclaris Therapeutics, Inc.NCT03687372Written as A-101How we know
- A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa NigraCompletedPhase 2Aclaris Therapeutics, Inc.NCT03224598Written as A-101 Topical Solution 40%How we know
- An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic KeratosesCompletedPhase 4Aclaris Therapeutics, Inc.NCT03487588Written as A-101 Topical SolutionHow we know
- A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic KeratosisCompletedPhase 2Aclaris Therapeutics, Inc.NCT03148691Written as A-101How we know
- A Phase2 of A-101 Topical Solution in Subjects With Common WartsCompletedPhase 2Aclaris Therapeutics, Inc.NCT03210337Written as A-101 Topical SolutionHow we know
- A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common WartsCompletedPhase 2Aclaris Therapeutics, Inc.NCT03278028Written as A-101 Topical SolutionHow we know
- Dose-Response Profile of A-101 in Subjects With Seborrheic KeratosisCompletedPhase 2Aclaris Therapeutics, Inc.NCT02160626Written as A-101 (40) Topical SolutionHow we know
- Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic KeratosisCompletedPhase 1/2Aclaris Therapeutics, Inc.NCT01986920Written as A-101 25%How we know
- A Study of A-101 Solution in Subjects With Common Warts.CompletedPhase 2Aclaris Therapeutics, Inc.NCT02669862Written as A-101 Solution 40How we know
- An Open-Label Safety Study of A-101 SolutionCompletedPhase 3Aclaris Therapeutics, Inc.NCT02667288Written as A-101 SolutionHow we know
- A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.CompletedPhase 3Aclaris Therapeutics, Inc.NCT02667236Written as A-101 SolutionHow we know
- A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic KeratosisCompletedPhase 3Aclaris Therapeutics, Inc.NCT02667275Written as A-101 SolutionHow we know